Top Mid Cap Stocks to Buy

Apogee Therapeutics continues to demonstrate exceptional 10x growth potential, with its recent positive 16-week Phase 2 APEX data for zumilokibart in atopic dermatitis reinforcing its best-in-class thesis in a multi-billion dollar market. The pivotal $1.3 billion strategic financing collaboration with Blackstone Life Sciences, described as non-dilutive for its royalty component, significantly de-risks its financial runway, providing ample capital for clinical development and commercialization efforts. While pre-revenue and reporting net losses (Q1 2026 EPS of -$1.06), its robust cash position and consistent execution on milestones foster high conviction for a substantial market re-rating as it progresses toward BLA submission. The CEO's insider selling (pre-Blackstone/data) is noted but does not outweigh the strong fundamental catalysts.

Atour Lifestyle Holdings Ltd (ATAT) maintains its strong trajectory as a high-growth, high-potential investment. The company's Q4 and FY 2025 results underscore its exceptional performance, with revenue growth exceeding 35% YoY and strong profitability (16.58% net margin, 46.96% ROE). Its scalable 'manachised' model continues to drive rapid network expansion and market leadership in China's premium lifestyle hotel segment, significantly expanding its total addressable market. The recent disclosure of Norges Bank's substantial stake further validates institutional confidence. While regulatory risks for Chinese ADRs persist, ATAT's consistent execution, asset-light model, and commitment to shareholder returns via its dividend policy position it strongly for continued market share gains and potential 10x growth within 3-5 years, especially with its burgeoning retail business adding diversification.